Drug intelligence / Profile preview

medium-chain triglycerides + long-chain triglycerides

Development stage
Phase 2
Lead developer
Fresenius Kabi
Modality
Nanoparticles → Drug Delivery Systems, Small Molecules
Administration
Intravenous
01

Overview

Medium-chain triglycerides + long-chain triglycerides is a combination lipid emulsion used primarily as a source of calories and essential fatty acids in patients requiring parenteral nutrition when oral or enteral feeding is not possible, insufficient, or contraindicated. The formulation combines the rapid metabolism and easy absorption of medium-chain triglycerides (MCTs) with the essential fatty acid content of long-chain triglycerides (LCTs). This combination provides an efficient energy source for critically ill patients and those with malabsorption syndromes. In clinical use, these emulsions are found to be safe and effective for providing nutritional support in various patient populations including neonates, adults with gastrointestinal disorders, critically ill patients in intensive care units, and those recovering from surgery. The mechanism involves supplying readily oxidizable fatty acids (from MCTs) for quick energy production while LCTs provide essential fatty acids necessary for physiological functions[1][3][4][6]. Some formulations are also used as vehicles for intravenous drugs such as propofol.

Brand names
Lipofundin MCT/LCTFresofol 1% MCT/LCT
Other names
MCT/LCT emulsionmedium- and long-chain triglyceride emulsion

Beyond the preview

Go deeper on medium-chain triglycerides + long-chain triglycerides.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on medium-chain triglycerides + long-chain triglycerides.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call